Arrowhead Pharmaceuticals, Inc. is a pharmaceutical company based in the United States. They focus on developing medicines to treat genetic diseases by targeting the overproduction of proteins. With a risk rating score of 25.8, they are considered a medium-risk company. Arrowhead Pharmaceuticals' portfolio includes treatments for various conditions such as hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis, angioedema, and cardiovascular disease. Their innovative approach to gene targeting sets them apart in the industry.